A phase 2, Randomized, double-blind, Placebo-Controlled study to evaluate the effect of Add-on AMG 747 on schizophrenia negative symptoms- Pharmacogenetic sub study [SUBSTUDY OF 700215758]
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Tilapertin (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Pharmacogenomic; Therapeutic Use
- 23 Jun 2013 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
- 15 Apr 2013 Planned number of patients changed to 50.
- 15 Apr 2013 New trial record